Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
The Parathyroid Glands00:59

The Parathyroid Glands

The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by producing...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Essential Information About Chronobiology and Chronotherapy for the Optimal Care of People With Bipolar Disorders: An Expert Consensus.

Bipolar disorders·2026
Same author

Validation of the Temper Outbursts/Irritability-2: A Two-Item Screener for Temper Outbursts and Irritability in Youth.

Journal of child and adolescent psychopharmacology·2026
Same author

Prevalence of GLP-1 Receptor Agonist Use Among Privately Insured Individuals With Mood Disorders.

The Journal of clinical psychiatry·2026
Same author

Examining Real-World Implementation of Measurement-Based Care and its Influence on Emergency Department Visit Risk Among Outpatients With Mood and Anxiety Disorders.

Administration and policy in mental health·2026
Same author

Is pharmacotherapy guideline concordance consistent across patients who received pragmatic treatment for major depressive disorder?

International journal of psychiatry in clinical practice·2026
Same author

Disparities in utilization of high-volume thyroid surgeons for Graves disease: a statewide analysis.

Journal of the Endocrine Society·2026

Related Experiment Video

Updated: Jun 25, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

Lithium therapy and hyperparathyroidism: an evidence-based assessment.

Brian D Saunders1, Erika F H Saunders, Paul G Gauger

  • 1Department of Surgery, Pennsylvania State Milton S. Hershey Medical Center, Penn State University College of Medicine, Mail Code H070, 500 University Drive, PO Box 850, Hershey, PA 17033-0850, USA. bsaunders@hmc.psu.edu

World Journal of Surgery
|March 3, 2009
PubMed
Summary

Chronic lithium use can cause hypercalcemia and hyperparathyroidism. Evidence supports screening patients for these conditions and considering surgical or nonsurgical treatments like calcimimetics.

Related Experiment Videos

Last Updated: Jun 25, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

Area of Science:

  • Endocrinology
  • Nephrology

Background:

  • Lithium therapy can disrupt calcium homeostasis.
  • Chronic lithium exposure is linked to a unique form of hyperparathyroidism.

Purpose of the Study:

  • To review the literature on lithium-associated hyperparathyroidism.
  • To provide evidence-based recommendations for management.

Main Methods:

  • Systematic electronic literature searches were conducted.
  • References were classified by level of evidence.

Main Results:

  • Evidence supports a link between lithium therapy and hypercalcemia/hyperparathormonemia.
  • Preoperative imaging and intraoperative hormone monitoring are recommended for surgical candidates.
  • Calcimimetic therapy may be an alternative to surgery.

Conclusions:

  • Screening for hypercalcemia in patients on chronic lithium therapy is recommended.
  • Surgical approaches should be guided by imaging and hormone monitoring.
  • Calcimimetic therapy offers a potential nonsurgical management option.